Prostate Cancer ADT Increases Bone Fracture Risk
Investigators examined the risk of bone fracture associated with different forms of androgen deprivation therapy.
Investigators examined the risk of bone fracture associated with different forms of androgen deprivation therapy.
Statin use in prostate cancer is attractive given their proven cardiovascular benefits and favorable toxicity profile, according to investigators.
Patients with comorbidities are not routinely included in clinical trials.
Investigators reported findings from the first randomized trial to evaluate the use of metastasis-directed therapy with hormone therapy in patients with oligometastatic prostate cancer.
Pooled analysis of 12 randomized trials suggests use of concurrent/adjuvant androgen deprivation therapy in combination with prostate-only radiotherapy may improve outcomes
Greater effort should be directed at detecting and aggressively treating prostate cancer metastasis earlier, an approach made possible with the advent of highly sensitive and specific molecular imaging techniques and potent anticancer agents.
Investigators characterized practice patterns in the first-line treatment of nonmetastatic castration-resistant prostate cancer using real-world data.
Increase in survival of men with mCSPC during 2015-2019 coincides with the use of docetaxel and novel hormonal therapies for this disease state.
Adding a longer course of androgen deprivation therapy to postoperative radiotherapy may prolong metastasis-free survival in patients with prostate cancer.
Risk increased for CVD death and for death from ischemic heart disease and stroke, especially among those aged 70 to 79 years